Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 694,600 shares, a decline of 61.6% from the February 13th total of 1,810,000 shares. Based on an average daily trading volume, of 3,830,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.7% of the shares of the stock are short sold.
Institutional Trading of Xilio Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of XLO. Gilead Sciences Inc. acquired a new position in shares of Xilio Therapeutics in the fourth quarter worth $8,696,000. Takeda Pharmaceutical Co. Ltd. purchased a new stake in Xilio Therapeutics during the 4th quarter worth about $1,416,000. Trustees of Columbia University in the City of New York acquired a new position in Xilio Therapeutics in the 4th quarter valued at about $238,000. Geode Capital Management LLC lifted its holdings in Xilio Therapeutics by 85.0% in the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after purchasing an additional 155,337 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its holdings in Xilio Therapeutics by 26.0% in the 4th quarter. Balyasny Asset Management L.P. now owns 343,230 shares of the company’s stock valued at $328,000 after purchasing an additional 70,744 shares in the last quarter. Hedge funds and other institutional investors own 54.29% of the company’s stock.
Xilio Therapeutics Price Performance
Shares of XLO stock opened at $0.80 on Friday. The business’s fifty day moving average price is $0.93 and its 200 day moving average price is $0.94. The firm has a market capitalization of $35.18 million, a PE ratio of -0.47 and a beta of -0.38. Xilio Therapeutics has a 1-year low of $0.58 and a 1-year high of $1.93.
Xilio Therapeutics Company Profile
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.
Read More
- Five stocks we like better than Xilio Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What is MarketRank™? How to Use it
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Expert Stock Trading Psychology Tips
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.